BeOne Medicines Ltd. 4

SVP and General Counsel Lee Chan Henry exercised options into ordinary shares and sold 1,669 ADS of BeOne Medicines Ltd. on July 22, 2026 under a Rule 10b5-1 plan.

On July 22, 2026, Lee Chan Henry, SVP and General Counsel of BeOne Medicines Ltd., exercised three tranches of stock options covering an aggregate 21,697 ordinary shares (represented as American Depositary Shares) at exercise prices of $14.96, $16.41, and $12.23 per ordinary share, and immediately sold 1,669 ADS for liquidity under a pre-arranged Rule 10b5-1 trading plan. The filing shows multiple “M” coded transactions adding 514, 665, and 490 ADS to his direct holdings, followed by a single “S” coded sale of 1,669 ADS at $325 per ADS, implying an approximate sale value of about $542,425 and an underlying exercised value in the low seven figures when including the ordinary shares received from option exercises. After these transactions, Lee directly owns 338,884 ordinary shares, which, using the $325 per ADS reference price and the 13:1 ratio of ordinary shares to each ADS, implies an estimated post‑transaction holding value of roughly $8.5 million, indicating that despite the sale, he retains a substantial equity stake in the company.

Filing Facts

CIK

1651308

Ticker

ONC

Form

4

Source Type

fda

Accession

0001980648-26-000019

Alert Tier

6